|
Patent landscape, scope, and claims: |
Scope and claims of U.S. Patent 12,403,182 (PTH1-34 conjugate liquid formulation) and the US patent landscape for the specific formulation and manufacturing process
Executive summary
- U.S. Patent 12,403,182 is directed to a liquid pharmaceutical formulation containing a PTH conjugate where the PTH moiety is PTH1-34 (SEQ ID NO:51) and where the conjugate includes a linker/auxiliary moiety defined by m and p = integers 400-500, plus succinic acid, D-mannitol, and m-cresol at specific concentrations and a target pH ~4.0 (with “about” meaning ±10%).
- The patent includes (i) formulation claims, (ii) a manufacturing method with an order-of-steps limitation that is optionally reversible in one claim but not reversed in a dependent claim, and (iii) broad medical use claims for diseases treatable by PTH, with hypoparathyroidism called out explicitly.
- A key narrowness driver is the exact composition/parameter set: PTH1-34 conjugate identity + concentration targets for succinic acid (~1.18 mg/mL), D-mannitol (~41.7 mg/mL), m-cresol (~2.5 mg/mL) and pH ~4.0, with “about” ±10%, plus a specific conjugate architecture (amide linkage to the N-terminus and the defined m/p range).
- For infringement risk, the manufacturing steps (including pH adjustment and optional filtration) and the “free of an antioxidant” dependent claim can create enforceable barriers for competitors if they replicate the exact product profile and process decision points.
What is U.S. Patent 12,403,182 about and what is the core inventive concept?
Featured snippet answer: The patent claims a specific aqueous liquid formulation of a PTH1-34 conjugate with succinic acid, D-mannitol, and m-cresol at defined concentrations and pH ~4.0, plus manufacturing steps for preparing and dosing that liquid.
Claim set structure (what is claimed)
The claims you provided break into three buckets:
-
Product (liquid formulation) claims
- Claim 1: Composition with defined PTH conjugate structure, succinic acid, D-mannitol, m-cresol, and pH ~4.0, with PTH moiety = PTH1-34 (SEQ ID NO:51) and conjugate linkage defined by amide bonding to the N-terminal amine.
- Claim 7: Narrows claim 1 by restating that the conjugate structure has m and p integers 400-500 (making explicit the architecture constraints).
- Claim 8: Narrows claim 1 by adding “free of an antioxidant.”
-
Process claims (manufacturing the liquid formulation)
- Claim 2: Manufacturing steps: admixing PTH conjugate + succinic acid + D-mannitol + m-cresol; adjust pH; optionally filter; transfer into containers; seal. It states the order of pH adjustment vs filtration is optionally reversible.
- Claim 3: Dependent limitation that steps (ii) and (iii) are not reversed, i.e., pH adjustment occurs before filtration (or at least preserves a specific order).
-
Method-of-use claims
- Claim 4: Broad medical use: treating, controlling, delaying, or preventing diseases treated by PTH by administering the formulation of claim 1.
- Claim 5: Disease list including hypoparathyroidism, hyperphosphatemia, osteoporosis variants, fracture repair, osteomalacia, Paget’s disease, osteoarthritis, rheumatoid arthritis, Paget’s disease, bone fracture, periodontitis, osteonecrosis of jaw, and “poorly healing fractures due to ALPL gene mutations.”
- Claim 6: Dependent narrowing to hypoparathyroidism.
Core inventive concept implied by the claim limitations
The combination of:
- a PTH1-34 conjugate (not native PTH1-34 alone),
- with a conjugate structure defined by m and p (400-500),
- formulated with a specific set of excipients (succinic acid, D-mannitol, m-cresol),
- at specific concentrations and pH ~4.0, and
- with an optional but specific manufacturing flow (admix, pH adjust, optional filtration, fill/containment)
creates a profile that is typically hard to replicate without deliberate design.
What is the exact claim scope for the liquid pharmaceutical formulation (Claim 1)?
Featured snippet answer: Claim 1 covers a liquid containing a PTH1-34 (SEQ ID NO:51) conjugate linked via an amide bond to the PTH N-terminal amine, where the conjugate includes a segment with m and p = 400-500, formulated with succinic acid (~1.18 mg/mL), D-mannitol (~41.7 mg/mL), m-cresol (~2.5 mg/mL) and pH ~4.0, with “about” ±10%.
Conjugate identity constraints (structural gating)
Claim 1 requires:
- A “PTH conjugate” of a formula (not fully reproduced in your prompt, but constrained by attachment and moieties).
- An unmarked dashed line indicates attachment by an amide bond to the N-terminal amine of a PTH moiety.
- The PTH moiety is PTH1-34 (SEQ ID NO:51).
- The “dashed line marked with an asterisk indicates attachment to a moiety wherein m and p are independently an integer from 400 to 500.”
- These constraints mean the patent is not merely about a formulation containing any PTH conjugate; it is about a conjugate with defined end-group/attachment architecture and a quantified m/p range.
Quantitative formulation constraints (parameter gating)
Claim 1 includes approximate concentrations:
- PTH conjugate at about 0.3 mg/mL (stated as “about 0.3 mg/ml mg/ml” in your text, which reads as intended “0.3 mg/mL”).
- Succinic acid at about 1.18 mg/mL
- D-mannitol at about 41.7 mg/mL
- m-cresol at about 2.5 mg/mL
- pH about 4.0
- “about” means ±10% of stated value.
Implication for scope: A product with pH drifting beyond the ±10% concept is outside claim 1. The same applies to the excipient concentrations and the PTH conjugate concentration. The patent is therefore likely to be “composition-and-range” specific rather than functional-excipient generic.
How Claim 7 changes the scope
Claim 7 restates and narrows the conjugate architecture by explicitly requiring:
- attachment to a moiety where m and p are integers 400-500 (already present in Claim 1). Functionally, Claim 7 is an additional convergence point, reducing arguments about interpretive ambiguity.
How Claim 8 changes the scope (“free of an antioxidant”)
Claim 8 adds a negative limitation:
- The formulation is “free of an antioxidant.”
Infringement impact: If a competitor uses any antioxidant (commonly included in protein/peptide formulations such as methionine, ascorbate, tocopherol derivatives, chelators with antioxidant function depending on definition, etc.), the product may fall outside claim 8. Note: Claim 8 is dependent, so even if omitted antioxidants are not used, claim 1 may still be infringed unless the “free of antioxidant” is a required feature only for claim 8.
What are the manufacturing process limits in Claim 2 and Claim 3?
Featured snippet answer: Claim 2 covers a manufacturing method: admix PTH conjugate with succinic acid, D-mannitol, and m-cresol; adjust pH; optionally filter; transfer aliquots into containers; seal; with pH adjustment and optional filtration optionally reversed. Claim 3 tightens by requiring the steps are not reversed.
Claim 2 step logic
- (i) Admix PTH conjugate with succinic acid, D-mannitol, and m-cresol
- (ii) Adjust pH of the admixture
- (iii) Optionally filter the admixture
- (iv) Transfer amounts equivalent to desired number of dosages into a container
- (v) Seal the container
Order control: Claim 2 states “order of steps (ii) and (iii) may optionally be reversed.” That yields two embodiments:
- pH adjust then filter, or
- filter then pH adjust.
Claim 3 tightens order
Claim 3 says steps (ii) and (iii) are not reversed. That forces a single embodiment:
- pH adjustment occurs in a specified order relative to filtration.
Enforcement leverage: Process claims often provide leverage when a formulation is difficult to prove directly. Here, if a competitor uses the same composition but changes whether pH is adjusted before or after filtration, it may avoid Claim 3 while remaining exposed to Claim 2 (depending on whether their exact process matches one of Claim 2’s embodiments).
What is the treatment/use claim scope (Claims 4-6) and how broad is it?
Featured snippet answer: Claim 4 covers administering the claim 1 formulation to treat, control, delay, or prevent PTH-treatable diseases. Claim 5 provides a non-limiting-looking but enumerated list of diseases, including hypoparathyroidism and multiple bone metabolic disorders. Claim 6 narrows to hypoparathyroidism.
Claim 4: functional disease category
- The method includes “one or more diseases which can be treated by PTH.”
- That is a wide tie to the pharmacology of PTH (parathyroid hormone pathway), not a single indication.
Claim 5: specific disease list
The list in your prompt is long and covers:
- Hypoparathyroidism
- Hyperphosphatemia
- Osteoporosis and variants (including steroid-induced, male osteoporosis)
- Fracture repair
- Osteomalacia
- Arthritis, osteoarthritis, rheumatoid arthritis
- Osteogenesis imperfecta
- Fibrous dysplasia
- Paget’s disease
- Humoral hypercalcemia associated with malignancy
- Osteopenia
- Periodontal disease
- Bone fracture
- Alopecia (including chemotherapy-induced alopecia)
- Thrombocytopenia (claimed)
- Chronic periodontitis
- Osteonecrosis of jaw
- Poorly healing fractures due to ALPL gene mutations
Claim 6: hypoparathyroidism focus
This is the only indication explicitly singled out in a dependent claim in your list.
Commercial takeaway: Hypoparathyroidism is typically the cleanest path for enforcement and regulatory alignment in PTH products. Broader lists can support licensing leverage even if they never all map to approved labeling.
What does this claim language imply about novelty and likely earlier priority targets?
Even without the full text of the patent specification, the constraints in claims 1-8 point to what the patent likely considered novel:
- A specific PTH conjugate architecture including N-terminal amide attachment and m/p range 400-500
- A specific acidic pH liquid regime near pH 4
- A defined succinic acid / D-mannitol / m-cresol composition
- A manufacturing step order limitation around pH adjustment and filtration
- A packaging and sealing step typical of sterile injectables but claimed as part of method-of-manufacture
In practical freedom-to-operate terms, infringement will usually require a competitor to:
- use the same or an equivalent conjugate identity,
- formulate to the same concentration and pH envelope, and
- (for certain claims) follow the same process order.
What is the US patent landscape likely to look like around this claim set?
No additional bibliographic data (publication number, assignee, priority dates, continuation status, related family members, and Orange Book/NDA linkage) was provided. Without those identifiers, a complete landscape cannot be produced without guessing.
What can be stated strictly from the claim content is the type of IP cluster that usually surrounds this kind of product:
- Conjugate chemistry patents: defining PTH1-34 conjugation, linker attachment sites, and quantitative segment parameters like m and p.
- Formulation patents: defining excipient selection, concentrations, and pH windows for liquid stability.
- Sterile manufacturing/process patents: order of mixing, pH adjustment, filtration, and fill/finish controls.
- Method-of-use patents: PTH delivery claims across indications.
For competitive planning, the scope of U.S. 12,403,182 implies that the most relevant competitor entry attempts would be:
- “Same PTH conjugate, different excipients” (try to avoid succinic acid / mannitol / m-cresol + pH match).
- “Same excipients, different pH” (shift outside pH ~4.0 ±10% envelope concept).
- “Same formulation, different process order” (avoid the exact filtration vs pH ordering for Claim 3, while still possibly exposing them to Claim 2).
- “Same formulation, antioxidant present” (avoid Claim 8, but not necessarily Claim 1).
- “Different conjugate architecture” (change m/p range or attachment site to avoid the conjugate constraints of Claims 1 and 7).
Key Takeaways
- U.S. 12,403,182 is a composition-and-range patent for a liquid PTH1-34 conjugate formulation with defined succinic acid, D-mannitol, and m-cresol concentrations and pH ~4.0.
- The conjugate scope is gated by amide attachment to PTH1-34 N-terminus and a moiety with m and p independently 400-500.
- Manufacturing IP is present: pH adjustment and optional filtration ordering is flexible in Claim 2 but fixed in Claim 3.
- The medical-use claims are broad and include hypoparathyroidism explicitly.
- Dependent limitations such as “free of an antioxidant” (Claim 8) and “not reversed” step order (Claim 3) create additional design-around pathways.
FAQs
- If a competitor matches the excipients and pH but uses a different PTH conjugate than PTH1-34 (SEQ ID NO:51), does it fall outside claim 1?
- How does adding an antioxidant affect risk under Claim 8 versus Claim 1?
- If filtration occurs before pH adjustment, which claim(s) are most implicated under the process section?
- What is the practical design-around strategy if m and p are outside 400-500?
- Is the method-of-use coverage limited by the listed indications or tied to any PTH-treatable disease?
References
- US Patent 12,403,182 (claim text provided in prompt).
More… ↓
⤷ Start Trial
|
